STORM Therapeutics selects first-in-class clinical candidate targeting METTL3

STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, today announces that STC-15, its first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies. The Company intends to submit an IND application in 2021.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH